Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 On Track to Submit IND in Choroidal Metastasis in 2H 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data … [Read more…]
